A Phase III Confirmatory Study of K-877 Extended Release Tablet

PHASE3CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

September 25, 2021

Study Completion Date

September 25, 2021

Conditions
Dyslipidemias
Interventions
DRUG

K-877 ER 0.2 mg/day (once daily)

K-877 ER 0.2 mg tablet

DRUG

K-877 ER 0.4 mg/day (once daily)

K-877 ER 0.4 mg tablet

DRUG

K-877 IR 0.2 mg/day (twice daily)

K-877 IR 0.1 mg tablet

Trial Locations (11)

Unknown

Institute Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic, Kanagawa

Medical Corporation Heishinkai OCROM Clinic, Osaka

Dojinkinenkai Meiwa Hospital, Tokyo

Fukuwa Clinic, Tokyo

Ikebukuro Metropolitan Clinic, Tokyo

Medical Corp. Seikoukai New Medical Research System Clinic, Tokyo

Medical Corporation Asbo Tokyo Asbo Clinic, Tokyo

Medical Corporation Chiseikai Tokyo Center Clinic, Tokyo

Medical Corporation Heishinkai ToCROM Clinic, Tokyo

Medical Corporation Yuhokai Miho Clinic, Tokyo

Tokyo-Eki Center-building Clinic, Tokyo

All Listed Sponsors
lead

Kowa Company, Ltd.

INDUSTRY

NCT04714151 - A Phase III Confirmatory Study of K-877 Extended Release Tablet | Biotech Hunter | Biotech Hunter